Follow the 유바이오로직스 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 유바이오로직스 has published 74 insider filings. Market capitalisation: €290.8bn. The latest transaction was reported on 3 April 2026 (Purchase). Among the most active insiders: 바이오노트. The full history is openly available.
74
Insider Decl.
n/a
Thresholds
n/a
64 ops.
Buy Volume
n/a
1 ops.
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 209 of 28,134 companies
88.4
score / 100
Value
90
Quality
87
FCF yld11%
Earn yld14%
EV/EBITDA4.6x
ROE·
Gross mgn58%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
유바이오로직스 is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biological solutions.